Brain natriuretic peptide as bridge to therapy for heart failure

Lancet

Volumn 355, Issue 9210, 2000, Pages 1112-1113

  Dries, D L ^a   Stevenson, L W ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; SPIRONOLACTONE; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; DISEASE MARKER; HEART FAILURE; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; NONHUMAN; NOTE; PRIORITY JOURNAL;

EID: 0034176732     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02053-5     Document Type: Note

References (14)

1. BS Edwards RS Zimmerman TR Schwab DM Heublein JC Burnett Jr. Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor Circ Res 62 1988 191 195
2. JC Burnett Jr Atrial natriuretic factor: implications in congestive heart failure and hypertension I Hum Hypertens 3 suppl 1 1989 41 46
3. JC Burnett Jr Atrial natriuretic factor: is it physiologically important? Circulation 82 1990 1523 1524
4. T Tsutamoto K Bito M Kinoshita Plasma atrial natriuretic polypeptide as an index of left ventricular end-diastolic pressure in patients with chronic left-sided heart failure Am Heart I 117 1989 599 606
5. K Yamamoto JC Burnett Jr M Jougasaki Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy Hypertension 28 1996 988 994
6. CM Yu JE Sanderson IO Shum Diastolic dysfunction and natriuretic peptides in systolic heart failure: higher ANP and BNP levels are associated with the restrictive filling pattern Eur Heart I 17 1996 1694 1702
7. PL Selvais JE Donckier A Robert Cardiac natriuretic peptides for diagnosis and risk stratification in heart failure: influences of left ventricular dysfunction and coronary artery disease on cardiac hormonal activation Eur I Clin Invest 28 1998 636 642
8. T Tsutamoto A Wada K Maeda Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction: comparison with plasma angiotensin II and endothelin-I Eur Heart I 20 1999 1799 1807
9. DR Murdoch TA McDonagh J Byrne Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy Am Heart I 138 1999 1126 1132
10. LW Stevenson JH Tillisch M Hamilton Importance of hemodynamic response to therapy in predicting survival with ejection fraction less than or equal to 20% secondary to ischemic or nonischemic dilated cardiomyopathy Am I Cardiol 66 1990 1348 1354
11. MS Weinfeld GM Chertow LW Stevenson Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure Am Heart I 138 1999 285 290
12. A Wada T Tsutamoto Y Matsuda M Kinoshita Cardiorenal and neurohumoral effects of endogenous atrial natriuretic peptide in dogs with severe congestive heart failure using a specific antagonist for guanylate cyclase-coupled receptors Circulation 89 1994 2232 2240
13. T Tsutamoto A Wada K Maeda Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction Circulation 96 1997 509 516
14. T Tsutamoto T Kanamori A Wada N Miyauchi T Murata M Kinoshita Limitations of compensation by endogenous atrial natriuretic peptide in heart failure Ipn Circ I 56 1992 489 493